Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Around 2.3 million Medicare patients used Novo drugs made with semaglutide - which includes Ozempic, Wegovy and Rybelsus ... Shares in Novo Nordisk were already down before the publication ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk, meanwhile, faced a 5% share price decline on Friday after outgoing U.S. president Joe Biden announced the company’s semaglutide drug, the medication used in Wegovy and Ozempic ...

Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China ... Novo Nordisk is the sole owner of semaglutide, the active ingredient in both Ozempic ...

The company's most famous brands, Wegovy and Ozempic, are both GLP-1s ... AstraZeneca's potentially lower sales in China in the coming quarters -- Novo Nordisk's revenue could grow faster than ...

Ozempic. Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly spoken of the U.S. taking Greenland off Denmark’s hands. Danish ...